33 results on '"Gualandi, A."'
Search Results
2. Whole-exome sequencing in patients with protein aggregate myopathies reveals causative mutations associated with novel atypical phenotypes.
- Author
-
Machnicki, Marcin M., Guglielmi, Valeria, Pancheri, Elia, Gualandi, Francesca, Verriello, Lorenzo, Pruszczyk, Katarzyna, Kosinska, Joanna, Sangalli, Antonella, Rydzanicz, Malgorzata, Romanelli, Maria Grazia, Neri, Marcella, Ploski, Rafal, Tonin, Paola, Tomelleri, Giuliano, Stoklosa, Tomasz, and Vattemi, Gaetano
- Subjects
PHENOTYPES ,AMINO acid sequence ,MUSCLE diseases ,GENETIC mutation ,MISSENSE mutation - Abstract
Background: Myofibrillar myopathies (MFM) are a subgroup of protein aggregate myopathies (PAM) characterized by a common histological picture of myofibrillar dissolution, Z-disk disintegration, and accumulation of degradation products into inclusions. Mutations in genes encoding components of the Z-disk or Z-disk-associated proteins occur in some patients whereas in most of the cases, the causative gene defect is still unknown. We aimed to search for pathogenic mutations in genes not previously associated with MFM phenotype. Methods: We performed whole-exome sequencing in four patients from three unrelated families who were diagnosed with PAM without aberrations in causative genes for MFM. Results: In the first patient and her affected daughter, we identified a heterozygous p.(Arg89Cys) missense mutation in LMNA gene which has not been linked with PAM pathology before. In the second patient, a heterozygous p.(Asn4807Phe) mutation in RYR1 not previously described in PAM represents a novel, candidate gene with a possible causative role in the disease. Finally, in the third patient and his symptomatic daughter, we found a previously reported heterozygous p.(Cys30071Arg) mutation in TTN gene that was clinically associated with cardiac involvement. Conclusions: Our study identifies a new genetic background in PAM pathology and expands the clinical phenotype of known pathogenic mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. 6 minute walk test in Duchenne MD patients with different mutations: 12 month changes
- Author
-
Claudio Bruno, Tiziana Mongini, Silvia Frosini, Sonia Messina, Enrica Rolle, Stefano C. Previtali, Francesca Gualandi, Roberto De Sanctis, Marika Pane, Gian Luca Vita, Filippo Cavallaro, Adele D'Amico, Paola D'Ambrosio, Angela Berardinelli, Roberta Battini, Luca Bello, Giovanni Baranello, Lucia Morandi, Giacomo P. Comi, Luisa Politano, Maria Teresa Arnoldi, Enrico Bertini, Elena S. Mazzone, Francesca Rossi, Concetta Palermo, Nathalie Goemans, Marlene Van der Haawue, Antonella Pini, Maria Alice Donati, Alessandra Ferlini, Yvan Torrente, Elena Pegoraro, Chiara Alfonsi, Roberta Scalise, Maria Pia Sormani, Eugenio Mercuri, Francesca Magri, Serena Bonfiglio, Michele Sacchini, Valentina Lanzillotta, Sara Napolitano, Lavinia Fanelli, Flaviana Bianco, Emanuela Viggiano, Pane, M, Mazzone, E, Sormani, Mp, Messina, S, Vita, Gl, Fanelli, L, Berardinelli, A, Torrente, Y, D'Amico, A, Lanzillotta, V, Viggiano, E, D'Ambrosio, P, Cavallaro, F, Frosini, S, Bello, L, Bonfiglio, S, Scalise, R, De Sanctis, R, Rolle, E, Bianco, F, Van der Haawue, M, Magri, F, Palermo, C, Rossi, F, Donati, Ma, Alfonsi, C, Sacchini, M, Arnoldi, Mt, Baranello, G, Mongini, T, Pini, A, Battini, R, Pegoraro, E, Previtali, Sc, Napolitano, S, Bruno, C, Politano, Luisa, Comi, Gp, Bertini, E, Morandi, L, Gualandi, F, Ferlini, A, Goemans, N, and Mercuri, E.
- Subjects
Male ,Time Factors ,Duchenne muscular dystrophy ,Muscular Dystrophies ,Cohort Studies ,Dystrophin ,inglese ,Muscular dystrophy ,Child ,Multidisciplinary ,Statistics ,Neuromuscular Diseases ,Neurology ,Child, Preschool ,Cohort ,Observational Studies ,Medicine ,Cohort study ,Research Article ,Test Evaluation ,medicine.medical_specialty ,Adolescent ,Clinical Research Design ,Science ,Nonsense mutation ,changes ,Biostatistics ,walking ,Settore MED/39 - NEUROPSICHIATRIA INFANTILE ,Genetic Mutation ,Diagnostic Medicine ,Internal medicine ,medicine ,Genetics ,Humans ,Biology ,Clinical Genetics ,business.industry ,Point mutation ,Human Genetics ,X-Linked ,medicine.disease ,Clinical trial ,Muscular Dystrophy, Duchenne ,Mutation ,Physical therapy ,Observational study ,business ,Mathematics - Abstract
ObjectiveIn the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are specifically targeting distinct groups of mutations, such as deletions eligible for skipping of individual exons. The aim of this observational study was to establish whether patients with distinct groups of mutations have different profiles of changes on the 6 minute walk test (6MWT) over a 12 month period.MethodsThe 6MWT was performed in 191 ambulant DMD boys at baseline and 12 months later. The results were analysed using a test for heterogeneity in order to establish possible differences among different types of mutations (deletions, duplications, point mutations) and among subgroups of deletions eligible to skip individual exons.ResultsAt baseline the 6MWD ranged between 180 and 560,80 metres (mean 378,06, SD 74,13). The 12 month changes ranged between -325 and 175 (mean -10.8 meters, SD 69.2). Although boys with duplications had better results than those with the other types of mutations, the difference was not significant. Similarly, boys eligible for skipping of the exon 44 had better baseline results and less drastic changes than those eligible for skipping exon 45 or 53, but the difference was not significant.Conclusionseven if there are some differences among subgroups, the mean 12 month changes in each subgroup were all within a narrow Range: from the mean of the whole DMD cohort. This information will be of help at the time of designing clinical trials with small numbers of eligible patients.
- Published
- 2014
4. Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies
- Author
-
Eugenio Mercuri, Paolo Grumati, Francesca Gualandi, Luciano Merlini, Enrico Bertini, Patrizia Sabatelli, Matteo Bovolenta, Alessandra Ferlini, Marcella Neri, Anna Urciuolo, Paolo Bonaldo, E. Martoni, M. Fabris, Bovolenta, Matteo, Neri, Marcella, Martoni, Elena, Urciuolo, Anna, Sabatelli, Patrizia, Fabris, Marina, Grumati, Paolo, Mercuri, Eugenio, Bertini, Enrico, Merlini, Luciano, Bonaldo, Paolo, Ferlini, Alessandra, and Gualandi, Francesca
- Subjects
Male ,Intron ,Gene Dosage ,Genetic mutation ,Compound heterozygosity ,Muscular Dystrophies ,Cohort Studies ,Exon ,0302 clinical medicine ,Collagen VI ,Genetics(clinical) ,Copy-number variation ,Child ,Muscular Dystrophie ,Genetics (clinical) ,Oligonucleotide Array Sequence Analysis ,Allele ,Genetics ,Comparative Genomic Hybridization ,0303 health sciences ,Bethlem myopathy ,Middle Aged ,Immunohistochemistry ,Phenotype ,Child, Preschool ,Mutational analysis ,Muscular dystrophy ,Fibroblast ,Female ,Human ,Research Article ,Adult ,lcsh:Internal medicine ,Heterozygote ,lcsh:QH426-470 ,Adolescent ,Genotype ,Ullrich congenital muscular dystrophy ,Collagen Type VI ,Biology ,Genetic Heterogeneity ,03 medical and health sciences ,Muscular Diseases ,Intronic Mutation ,medicine ,Humans ,lcsh:RC31-1245 ,Alleles ,030304 developmental biology ,Muscular Disease ,Oligonucleotide Array Sequence Analysi ,Genetic heterogeneity ,Fibroblasts ,medicine.disease ,Introns ,lcsh:Genetics ,Mutation ,Cohort Studie ,Gene Deletion ,030217 neurology & neurosurgery - Abstract
Background Molecular characterization of collagen-VI related myopathies currently relies on standard sequencing, which yields a detection rate approximating 75-79% in Ullrich congenital muscular dystrophy (UCMD) and 60-65% in Bethlem myopathy (BM) patients as PCR-based techniques tend to miss gross genomic rearrangements as well as copy number variations (CNVs) in both the coding sequence and intronic regions. Methods We have designed a custom oligonucleotide CGH array in order to investigate the presence of CNVs in the coding and non-coding regions of COL6A1, A2, A3, A5 and A6 genes and a group of genes functionally related to collagen VI. A cohort of 12 patients with UCMD/BM negative at sequencing analysis and 2 subjects carrying a single COL6 mutation whose clinical phenotype was not explicable by inheritance were selected and the occurrence of allelic and genetic heterogeneity explored. Results A deletion within intron 1A of the COL6A2 gene, occurring in compound heterozygosity with a small deletion in exon 28, previously detected by routine sequencing, was identified in a BM patient. RNA studies showed monoallelic transcription of the COL6A2 gene, thus elucidating the functional effect of the intronic deletion. No pathogenic mutations were identified in the remaining analyzed patients, either within COL6A genes, or in genes functionally related to collagen VI. Conclusions Our custom CGH array may represent a useful complementary diagnostic tool, especially in recessive forms of the disease, when only one mutant allele is detected by standard sequencing. The intronic deletion we identified represents the first example of a pure intronic mutation in COL6A genes.
- Published
- 2010
5. De novo exonic duplication of ATP1A2 in Italian patient with hemiplegic migraine: a case report.
- Author
-
Gagliardi, Stella, Grieco, Gaetano, Gualandi, Francesca, Caniatti, Luisa, Groppo, Elisabetta, Valente, Marialuisa, Giuseppe, Nappi, Neri, Marcella, and Cereda, Cristina
- Subjects
GENEALOGY ,GENETIC techniques ,HEMIPLEGIA ,MIGRAINE ,GENETIC mutation ,PHENOTYPES - Abstract
Background: Sporadic Hemiplegic Migraine is a rare form of migraine headache. Mutations in three different genes, two ion-channel genes and one encoding an ATP exchanger, CACNA1A, ATP1A2 and SCN1A are all responsible for the FHM phenotype, thus indicating a genetic heterogeneity for this disorder. Here, we described a de novo exonic duplication of ATP1A2 in an Italian patient with Hemiplegic Migraine. Case presentation: We describe the case of a young woman (33 year old) who suffered from the age of 8 years of episodic weakness of the limbs, associated to other subjective and objective features. From aged 25, she developed neurological symptoms, like dizziness, blurred vision and an MRI scan revealed aspecific peritrigonal white matter hyperintensities. Aged 32 she suffered of right hemisomatic sudden-onset paresthesias, hypoesthesia and hyposthenia and the patient was genetically investigated for sporadic hemiplegic migraine. Conclusions: Here we report, for the first time, an exonic duplication in the ATP1A2 associated with hemiplegic migraine. The variation identified involves exon 21 of the ATP1A2 and is expected to alter the function of the alpha(2) subunit of the Na(+)/K(+) pump; the de novo nature of the duplication further supports its pathogenic role. To date, no other CNVs have been described in the ATP1A2 but only point mutations are reported. The novel mutation may result impaired M9 transmembrane domain, in a loss-of-function of the alpha(2) Na(+)/K(+)-ATPase with glutamate accumulation, alteration of synaptic function and neurotransmission. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Molecular study of human growth hormone gene cluster in three families with isolated growth hormone deficiency and similar phenotype.
- Author
-
Cacciari, Emanuele, Pirazzoli, Piero, Gualandi, Stefano, Zucchini, Stefano, Balsamo, Antonio, Cicognani, Alessandro, Baroncini, Claudia, Baldazzi, Lilia, Trevisani, Barbara, Capelli, Maurizio, Bernadi, Francesco, Cacciari, E, Pirazzoli, P, Gualandi, S, Baroncini, C, Baldazzi, L, Trevisani, B, Capelli, M, Zucchini, S, and Balsamo, A
- Subjects
ALLELES ,COMPARATIVE studies ,DOCUMENTATION ,GENES ,GROWTH disorders ,IMMUNOBLOTTING ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,NUCLEOTIDES ,NUCLEOTIDE separation ,POLYMERASE chain reaction ,RESEARCH ,PHENOTYPES ,EVALUATION research ,HUMAN growth hormone ,SEQUENCE analysis - Abstract
The growth hormone (GH) gene (hGH-N) cluster was analysed using polymerase chain reaction, Southern and polymorphism analysis in five patients (including two pairs of siblings) with extreme short stature and absence of GH secretion. Patients 1 and 2 (siblings) were homozygous for a large deletion removing four genes of the cluster: hGH-N, hCS-L, hCS-A and hGH-V. Both siblings produced high anti-GH antibody levels in response to exogenous GH therapy, followed by growth arrest a few months after starting replacement therapy. In patient 3 we detected a heterozygous deletion which involved three genes of the cluster (hCS-A, hGH-V, hCS-B) and left an intact hGH-N gene. Direct sequencing of hGH-N specific amplified fragments excluded the presence of any point mutations in exons and splicing regions. In patients 4 and 5 (sisters) our study did not demonstrate any gene deletions. Analysis of polymorphic restriction patterns in this family demonstrated that both sisters inherited the same alleles from the father but different alleles from the mother, suggesting that the defect was not linked to the hGH-N gene. These results confirm the difficulty of clinical identification of subjects with hGH-N deletion and underline the importance of DNA analysis in patients with absence of GH secretion and extreme growth retardation. [ABSTRACT FROM AUTHOR]
- Published
- 1994
- Full Text
- View/download PDF
7. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice.
- Author
-
Wein, Nicolas, Vulin, Adeline, Falzarano, Maria S, Szigyarto, Christina Al-Khalili, Maiti, Baijayanta, Findlay, Andrew, Heller, Kristin N, Uhlén, Mathias, Bakthavachalu, Baskar, Messina, Sonia, Vita, Giuseppe, Passarelli, Chiara, Gualandi, Francesca, Wilton, Steve D, Rodino-Klapac, Louise R, Yang, Lin, Dunn, Diane M, Schoenberg, Daniel R, Weiss, Robert B, and Howard, Michael T
- Subjects
DYSTROPHIN genetics ,GENE expression ,GENETIC mutation ,LABORATORY mice ,MUSCULAR dystrophy genetics ,MUSCULAR dystrophy treatment - Abstract
Most mutations that truncate the reading frame of the DMD gene cause loss of dystrophin expression and lead to Duchenne muscular dystrophy. However, amelioration of disease severity has been shown to result from alternative translation initiation beginning in DMD exon 6 that leads to expression of a highly functional N-truncated dystrophin. Here we demonstrate that this isoform results from usage of an internal ribosome entry site (IRES) within exon 5 that is glucocorticoid inducible. We confirmed IRES activity by both peptide sequencing and ribosome profiling in muscle from individuals with minimal symptoms despite the presence of truncating mutations. We generated a truncated reading frame upstream of the IRES by exon skipping, which led to synthesis of a functional N-truncated isoform in both human subject-derived cell lines and in a new DMD mouse model, where expression of the truncated isoform protected muscle from contraction-induced injury and corrected muscle force to the same level as that observed in control mice. These results support a potential therapeutic approach for patients with mutations within the 5′ exons of DMD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Antisense-Induced Messenger Depletion Corrects a COL6A2 Dominant Mutation in Ullrich Myopathy.
- Author
-
Gualandi, Francesca, Manzati, Elisa, Sabatelli, Patrizia, Passarelli, Chiara, Bovolenta, Matteo, Pellegrini, Camilla, Perrone, Daniela, Squarzoni, Stefano, Pegoraro, Elena, Bonaldo, Paolo, and Ferlini, Alessandra
- Subjects
- *
MUSCLE diseases , *COLLAGEN , *GENETIC mutation , *EXONS (Genetics) , *ANTISENSE RNA , *GENETIC polymorphisms - Abstract
AbstractCollagen VI gene mutations cause Ullrich and Bethlem muscular dystrophies. Pathogenic mutations frequently have a dominant negative effect, with defects in collagen VI chain secretion and assembly. It is agreed that, conversely, collagen VI haploinsufficiency has no pathological consequences. Thus, RNA-targeting approaches aimed at preferentially inactivating the mutated COL6 messenger may represent a promising therapeutic strategy. By in vitrostudies we obtained the preferential depletion of the mutated COL6A2 messenger, by targeting a common single-nucleotide polymorphism (SNP), cistronic with a dominant COL6A2 mutation. We used a 2?-O-methyl phosphorothioate (2?OMePS) antisense oligonucleotide covering the SNP within exon 3, which is out of frame. Exon 3 skipping has the effect of depleting the mutated transcript via RNA nonsense-mediated decay, recovering the correct collagen VI secretion and restoring the ability to form an interconnected microfilament network into the extracellular matrix. This novel RNA modulation approach to correcting dominant mutations may represent a therapeutic strategy potentially applicable to a great variety of mutations and diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies.
- Author
-
Bovolenta, Matteo, Neri, Marcella, Martoni, Elena, Urciuolo, Anna, Sabatelli, Patrizia, Fabris, Marina, Grumati, Paolo, Mercuri, Eugenio, Bertini, Enrico, Merlini, Luciano, Bonaldo, Paolo, Ferlini, Alessandra, and Gualandi, Francesca
- Subjects
INTRONS ,GENETIC mutation ,MUSCLE diseases ,MOLECULES ,GENES - Abstract
Background: Molecular characterization of collagen-VI related myopathies currently relies on standard sequencing, which yields a detection rate approximating 75-79% in Ullrich congenital muscular dystrophy (UCMD) and 60-65% in Bethlem myopathy (BM) patients as PCR-based techniques tend to miss gross genomic rearrangements as well as copy number variations (CNVs) in both the coding sequence and intronic regions. Methods: We have designed a custom oligonucleotide CGH array in order to investigate the presence of CNVs in the coding and non-coding regions of COL6A1, A2, A3, A5 and A6 genes and a group of genes functionally related to collagen VI. A cohort of 12 patients with UCMD/BM negative at sequencing analysis and 2 subjects carrying a single COL6 mutation whose clinical phenotype was not explicable by inheritance were selected and the occurrence of allelic and genetic heterogeneity explored. Results: A deletion within intron 1A of the COL6A2 gene, occurring in compound heterozygosity with a small deletion in exon 28, previously detected by routine sequencing, was identified in a BM patient. RNA studies showed monoallelic transcription of the COL6A2 gene, thus elucidating the functional effect of the intronic deletion. No pathogenic mutations were identified in the remaining analyzed patients, either within COL6A genes, or in genes functionally related to collagen VI. Conclusions: Our custom CGH array may represent a useful complementary diagnostic tool, especially in recessive forms of the disease, when only one mutant allele is detected by standard sequencing. The intronic deletion we identified represents the first example of a pure intronic mutation in COL6A genes. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
10. Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophy-related caveolin-3 P104L and TFT mutants
- Author
-
Fanzani, Alessandro, Stoppani, Elena, Gualandi, Laura, Giuliani, Roberta, Galbiati, Ferruccio, Rossi, Stefania, Fra, Anna, Preti, Augusto, and Marchesini, Sergio
- Subjects
MEMBRANE proteins ,CHEMICAL reactions ,MUSCLE cells ,GENETIC mutation - Abstract
Abstract: Caveolin-3 (Cav-3) is the main scaffolding protein present in myofiber caveolae. We transfected C2C12 myoblasts with dominant negative forms of Cav-3, P104L or ΔTFT, respectively, which cause the limb-girdle muscular dystrophy 1-C. Both these forms triggered Cav-3 loss during C2C12 cell differentiation. The P104L mutation reduced myofiber formation by impaired AKT signalling, accompanied by dramatic expression of the E3 ubiquitin ligase Atrogin. On the other hand, the ΔTFT mutation triggered hypertrophic myotubes sustained by prolonged AKT activation, but independent of increased levels of follistatin and interleukin 4 expression. These data suggest that separated mutations within the same dystrophy-related gene may cause muscle degeneration through different mechanisms. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
11. Occurrence of Del( GIB6 -D13S1830) Mutation in Italian Non-syndromic Hearing Loss Patients Carrying a Single GJB2 Mutated Allele.
- Author
-
Gualandi, F., Ravani, A., Berto, A., Burdo, S., Trevisi, P., Ferlini, A., Martini, A., and Calzolari, E.
- Subjects
- *
CONNEXINS , *GENETIC mutation , *HEARING disorders , *DIAGNOSIS , *PHENOTYPES , *MEDICAL screening - Abstract
Molecular screening for GJB2 (connexin 26) mutations represents the standard diagnostic approach for the genotype definition of non-syndromic deafness. Nevertheless, a single GJB2 pathogenic mutation is detectable in a relevant number of cases, therefore failing to explain the phenotype. We aimed at assessing the occurrence of the recently described del( GIB6 -D13S1830) mutation, occurring in the connexin 30 gene, in a group of Italian hearing-impaired patients carrying a single GJB2 mutated allele. A total of 59 non-syndromic hearing loss (NSHL) patients were screened for GJB2 mutations. Among these, nine NSHL patients were found to be heterozygous for a single GJB2 mutation. These patients, heterozygotes for different GJB2 mutated alleles (35delG, L90P, M34T, V153I), together with 11 additional 35delG/neg cases previously described, were studied for the presence of the del( GIB6 -D13S1830) mutation. Two double heterozygotes del( GIB6 -D13S1830)/35delG were identified. In both cases the degree of hearing loss was profound. Furthermore, GJB2 molecular screening led to the identification of a novel change (T55G) occurring in compound heterozygosity with the V37I mutation. In conclusion, our data suggest a significant frequency of del( GIB6 -D13S1830) mutation in Italian hearing-impaired subjects (10% of unexplained GJB2 heterozygotes) similar to that reported in other European countries. [ABSTRACT FROM AUTHOR]
- Published
- 2004
12. Progress in Understanding GJB2-Linked Deafness.
- Author
-
Gualandi, Francesca, Martini, Alessandro, and Calzolari, Elisa
- Subjects
- *
GENETICS of deafness , *MEDICAL genetics , *CONNEXINS , *GENETIC mutation , *GENETIC disorders - Abstract
Mutations in the GJB2 gene (encoding for Connexin 26 protein) represent a leading cause of genetic hearing impairment. Extensive epidemiological and molecular studies have been reported, describing GJB2 mutations type, frequency and distribution. Moreover, several aspects of GJB2 mutations pathogenic effects have been elucidated taking advantage of in vitro and in vivo experimental approaches. Progress through reported studies is reviewed, highlighting recent major achievements in this field. Attention is focused on different unresolved questions regarding GJB2 deafness pathogenesis and genotype-phenotype relationships. Clarification of these important clues will significantly increase our understanding of the molecular basis of hearing loss and will improve the effectiveness of diagnosis and counselling of this frequent disease. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
13. Mutation analysis of the MECP2 gene in British and Italian Rett syndrome females.
- Author
-
Vacca, Marcella, Filippini, Francesco, Budillon, Alberta, Rossi, Valeria, Mercadante, Grazia, Manzati, Elisa, Gualandi, Francesca, Bigoni, Stefania, Trabanelli, Cecilia, Pini, Giorgio, Calzolari, Elisa, Ferlini, Alessandra, Meloni, Ilaria, Hayek, Giuseppe, Zappella, Michele, Renieri, Alessandra, D'Urso, Michele, D'Esposito, Maurizio, MacDonald, Fiona, and Kerr, Alison
- Subjects
EPILEPSY ,GENETIC mutation ,INTELLECTUAL disabilities ,GENES ,MENTAL illness ,DISEASES in women - Abstract
Rett syndrome is an X-linked dominant neurological disorder, which appears to be the commonest genetic cause of profound combined intellectual and physical disability in Caucasian females. Recently, this syndrome has been associated with mutations of the MECP2 gene, a transcriptional repressor of still unknown target genes. Here we report a detailed mutational analysis of 62 patients from UK and Italian archives, representing the first comparative study among different populations and one of the largest number of cases so far analyzed. We review the literature on MECP2 mutations in Rett syndrome. This analysis has permitted us to produce a map of the recurrent mutations identified in this and previous studies. Bioinformatic analysis of the mutations, taking advantage of structural and evolutionary data, leads us to postulate the existence of a new functional domain in the MeCP2 protein, which is conserved among brain-specific regulatory factors. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
14. New CACNA1A deletions are associated to migraine phenotypes.
- Author
-
Grieco, G. S., Gagliardi, S., Ricca, I., Pansarasa, O., Neri, M., Gualandi, F., Nappi, G., Ferlini, A., and Cereda, C.
- Subjects
GENES ,MEDICAL needs assessment ,GENETIC mutation ,MIGRAINE ,PHENOTYPES ,SEQUENCE analysis ,SYMPTOMS ,GENETICS - Abstract
Background: Familial hemiplegic migraine type 1 (FHM1) is a form of migraine with aura caused by heterozygous mutations in 4 genes: CACNA1A, ATP1A2, SNC1A and PRRT2, but further heterogeneity is expected. Here have been described clinical and molecular features in patients suffering from migraine with Aura (MA), without (MO) and hemiplegic migraine attacks.Next Generation Sequencing by TruSeq Custom Amplicon for CACNA1A and ATP1A2 gene has been performed. All genetic variants have been confirmed by Sanger sequencing and all samples were also analyzed with MLPA assay for ATP1A2-CACNA1A genes to detect duplication or deletion. All MLPA data were verified by Real Time PCR.Results: Sequencing analysis showed 3 point mutations, two novel variants and one already described in literature. Moreover, MLPA analysis showed 3 deletions in 9 sporadic hemiplegic migraine (18%), in 3 patients with non-hemiplegic migraine (4.1%) and in 3 patients affected by episodic ataxia (20%). Two sporadic patients showed a deletion in exons 41-43, while the rest of HM patients (5) showed a deletion in the terminal part of the CACNA1A gene.About episodic ataxia, we have identified deletions in exon 12-15 and in exon 47. Finally, in migraine patients, we have found different subjects affected by different phenotypes deleted in exon 47.Conclusion: This work highlights the importance to complement analysis as direct sequencing with quantitative analysis (MLPA). In fact, intragenic CACNA1A rearrangements have been detected. Our work demonstrated that deletions in CACNA1A gene may be associated also to different migraine phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions.
- Author
-
Imbrici, Paola, Altamura, Concetta, Gualandi, Francesca, Mangiatordi, Giuseppe Felice, Neri, Marcella, De Maria, Giovanni, Ferlini, Alessandra, Padovani, Alessandro, D'Adamo, Maria Cristina, Nicolotti, Orazio, Pessia, Mauro, Conte, Diana, Filosto, Massimiliano, and Desaphy, Jean-Francois
- Subjects
- *
GENETIC mutation , *ATAXIA , *NEUROLOGICAL disorders -- Genetic aspects , *METABOLIC disorders , *GENETIC code , *GENETICS - Abstract
Episodic ataxia type 1 (EA1) is a human dominant neurological syndrome characterized by continuous myokymia, episodic attacks of ataxic gait and spastic contractions of skeletal muscles that can be triggered by emotional stress and fatigue. This rare disease is caused by missense mutations in the KCNA1 gene coding for the neuronal voltage gated potassium channel Kv1.1, which contributes to nerve cell excitability in the cerebellum, hippocampus, cortex and peripheral nervous system. We identified a novel KCNA1 mutation, E283K, in an Italian proband presenting with paroxysmal ataxia and myokymia aggravated by painful contractures and metabolic dysfunctions. The E283K mutation is located in the S3–S4 extracellular linker belonging to the voltage sensor domain of Kv channels. In order to test whether the E283K mutation affects Kv1.1 biophysical properties we transfected HEK293 cells with WT or mutant cDNAs alone or in a 1:1 combination, and recorded relative potassium currents in the whole-cell configuration of patch-clamp. Mutant E283K channels display voltage-dependent activation shifted by 10 mV toward positive potentials and kinetics of activation slowed by ~ 2 fold compared to WT channels. Potassium currents resulting from heteromeric WT/E283K channels show voltage-dependent gating and kinetics of activation intermediate between WT and mutant homomeric channels. Based on homology modeling studies of the mutant E283K, we propose a molecular explanation for the reduced voltage sensitivity and slow channel opening. Overall, our results suggest that the replacement of a negatively charged residue with a positively charged lysine at position 283 in Kv1.1 causes a drop of potassium current that likely accounts for EA-1 symptoms in the heterozygous carrier. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. SERCA1 protein expression in muscle of patients with Brody disease and Brody syndrome and in cultured human muscle fibers.
- Author
-
Guglielmi, Valeria, Vattemi, Gaetano, Gualandi, Francesca, Voermans, Nicol C., Marini, Matteo, Scotton, Chiara, Pegoraro, Elena, Oosterhof, Arie, Kósa, Magdolna, Zádor, Ernő, Valente, Enza Maria, De Grandis, Domenico, Neri, Marcella, Codemo, Valentina, Novelli, Antonio, van Kuppevelt, Toin H., Dallapiccola, Bruno, van Engelen, Baziel G., Ferlini, Alessandra, and Tomelleri, Giuliano
- Subjects
- *
ENDOPLASMIC reticulum , *GENE expression , *MUSCLE diseases , *HEREDITY , *ADENOSINE triphosphatase , *GENETIC mutation , *ALTERNATIVE RNA splicing , *PATIENTS - Abstract
Abstract: Brody disease is an inherited myopathy associated with a defective function of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 1 (SERCA1) protein. Mutations in the ATP2A1 gene have been reported only in some patients. Therefore it has been proposed to distinguish patients with ATP2A1 mutations, Brody disease (BD), from patients without mutations, Brody syndrome (BS). We performed a detailed study of SERCA1 protein expression in muscle of patients with BD and BS, and evaluated the alternative splicing of SERCA1 in primary cultures of normal human muscle and in infant muscle. SERCA1 reactivity was observed in type 2 muscle fibers of patients with and without ATP2A1 mutations and staining intensity was similar in patients and controls. Immunoblot analysis showed a significant reduction of SERCA1 band in muscle of BD patients. In addition we demonstrated that the wild type and mutated protein exhibits similar solubility properties and that RIPA buffer improves the recovery of the wild type and mutated SERCA1 protein. We found that SERCA1b, the SERCA1 neonatal form, is the main protein isoform expressed in cultured human muscle fibers and infant muscle. Finally, we identified two novel heterozygous mutations within exon 3 of the ATP2A1 gene from a previously described patient with BD. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
17. The medical genetics of dystrophinopathies: Molecular genetic diagnosis and its impact on clinical practice
- Author
-
Ferlini, Alessandra, Neri, Marcella, and Gualandi, Francesca
- Subjects
- *
MEDICAL genetics , *GENETIC mutation , *DYSTROPHIN genes , *BIOMARKERS , *MOLECULAR genetics , *GENETIC disorder diagnosis , *MEDICAL practice , *CARDIOMYOPATHIES - Abstract
Abstract: A large variety of mutations in the dystrophin gene cause Duchenne and Becker muscular dystrophies, diseases affecting predominantly the striated muscles (skeletal and cardiac). Rare mutations also account for the allelic disorder isolated X-linked dilated cardiomyopathy. Dystrophin protein is encoded by a huge gene located on the X chromosome and the understanding of its complex genomic architecture has unraveled general key functions in gene expression regulation. Dystrophin also exists as a number of other tissue specific isoforms, some exclusively or predominantly expressed in the brain and/or in other tissues. Genotype definition of the dystrophin gene in patients with dystrophinopathies has taught us much about functionally important domains of the protein itself and has also provided insights regarding several regulatory mechanisms governing the gene expression profile. This review focuses on the current understanding of the dystrophin mutations heterogeneity, genotype-phenotype correlations, as well as interpretation of the functional significance of mutations that often require non routine genetic studies. It also explores the impact of genetic diagnosis on clinical definition and on the discovery of biomarkers and personalized therapies. Our aim is to offer an overview of the medical genetic approach on the dystrophin gene and dystrophinopathies with implications for clinical practice and therapeutic perspectives. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
18. POPDC2 a novel susceptibility gene for conduction disorders.
- Author
-
Rinné, Susanne, Ortiz-Bonnin, Beatriz, Stallmeyer, Birgit, Kiper, Aytug K., Fortmüller, Lisa, Schindler, Roland F.R., Herbort-Brand, Ursula, Kabir, Nashitha S., Dittmann, Sven, Friedrich, Corinna, Zumhagen, Sven, Gualandi, Francesca, Selvatici, Rita, Rapezzi, Claudio, Arbustini, Eloisa, Ferlini, Alessandra, Fabritz, Larissa, Schulze-Bahr, Eric, Brand, Thomas, and Decher, Niels
- Subjects
- *
VENTRICULAR arrhythmia , *ATRIOVENTRICULAR node , *TWINS , *MYOCARDIUM , *GENETIC mutation , *SINOATRIAL node , *RECESSIVE genes - Abstract
Despite recent progress in the understanding of cardiac ion channel function and its role in inherited forms of ventricular arrhythmias, the molecular basis of cardiac conduction disorders often remains unresolved. We aimed to elucidate the genetic background of familial atrioventricular block (AVB) using a whole exome sequencing (WES) approach. In monozygotic twins with a third-degree AVB and in another, unrelated family with first-degree AVB, we identified a heterozygous nonsense mutation in the POPDC2 gene causing a premature stop at position 188 (POPDC2W188⁎), deleting parts of its cAMP binding-domain. Popeye-domain containing (POPDC) proteins are predominantly expressed in the skeletal muscle and the heart, with particularly high expression of POPDC2 in the sinoatrial node of the mouse. We now show by quantitative PCR experiments that in the human heart the POPDC-modulated two-pore domain potassium (K 2P) channel TREK-1 is preferentially expressed in the atrioventricular node. Co-expression studies in Xenopus oocytes revealed that POPDC2W188⁎ causes a loss-of-function with impaired TREK-1 modulation. Consistent with the high expression level of POPDC2 in the murine sinoatrial node, POPDC2W188⁎ knock-in mice displayed stress-induced sinus bradycardia and pauses, a phenotype that was previously also reported for POPDC2 and TREK-1 knock-out mice. We propose that the POPDC2W188⁎ loss-of-function mutation contributes to AVB pathogenesis by an aberrant modulation of TREK-1, highlighting that POPDC2 represents a novel arrhythmia gene for cardiac conduction disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. P.248 - Genetic landscapes in neuromuscular disorders: The influence of next-generation sequencing analysis.
- Author
-
Neri, M., Scotton, C., Gualandi, F., Wirth, B., Schols, L., Klockgether, T., Lochmuller, H., Muntoni, F., D'Amico, A., Bertini, E., Pane, M., Mercuri, E., and Ferlini, A.
- Subjects
- *
MYONEURAL junction , *MOLECULAR diagnosis , *GENETIC mutation , *NUCLEOTIDE sequencing , *CLINICAL trials ,NEUROMUSCULAR disease diagnosis - Published
- 2016
- Full Text
- View/download PDF
20. Defective collagen VI α6 chain expression in the skeletal muscle of patients with collagen VI-related myopathies.
- Author
-
Tagliavini, F., Pellegrini, C., Sardone, F., Squarzoni, S., Paulsson, M., Wagener, R., Gualandi, F., Trabanelli, C., Ferlini, A., Merlini, L., Santi, S., Maraldi, N.M., Faldini, C., and Sabatelli, P.
- Subjects
- *
MUSCLE diseases , *COLLAGEN , *GENETIC mutation , *SKELETAL muscle , *MUSCULAR dystrophy , *MUSCLE cell culture , *EXTRACELLULAR matrix , *GENE expression - Abstract
Collagen VI is a non-fibrillar collagen present in the extracellular matrix (ECM) as a complex polymer; the mainly expressed form is composed of α1, α2 and α3 chains; mutations in genes encoding these chains cause myopathies known as Ullrich congenital muscular dystrophy (UCMD), Bethlem myopathy (BM) and myosclerosis myopathy (MM). The collagen VI α6 chain is a recently identified component of the ECM of the human skeletal muscle. Here we report that the α6 chain was dramatically reduced in skeletal muscle and muscle cell cultures of genetically characterized UCMD, BM and MM patients, independently of the clinical phenotype, the gene involved and the effect of the mutation on the expression of the “classical” α1α2α3 heterotrimer. By contrast, the collagen VI α6 chain was normally expressed or increased in the muscle of patients affected by other forms of muscular dystrophy, the overexpression matching with areas of increased fibrosis. In vitro treatment with TGF-β1, a potent collagen inducer, promoted the collagen VI α6 chain deposition in the ECM of normal muscle cells, whereas, in cultures derived from collagen VI-related myopathy patients, the collagen VI α6 chain failed to develop a network outside the cells and accumulated in the endoplasmic reticulum. The defect of the α6 chain points to a contribution to the pathogenesis of collagen VI-related disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Brody syndrome: A clinically heterogeneous entity distinct from Brody disease: A review of literature and a cross-sectional clinical study in 17 patients
- Author
-
Voermans, N.C., Laan, A.E., Oosterhof, A., van Kuppevelt, T.H., Drost, G., Lammens, M., Kamsteeg, E.J., Scotton, C., Gualandi, F., Guglielmi, V., van den Heuvel, L., Vattemi, G., and van Engelen, B.G.
- Subjects
- *
MUSCLE diseases , *MUSCLE contraction , *LITERATURE reviews , *CROSS-sectional method , *GENETIC mutation , *PHENOTYPES , *PERIODIC health examinations , *SARCOPLASMIC reticulum , *PATIENTS - Abstract
Abstract: Brody disease is a rare inherited myopathy due to reduced sarcoplasmic reticulum Ca2+ ATPase (SERCA)1 activity caused by mutations in ATP2A1, which causes delayed muscle relaxation and silent cramps. So far the disease has mostly been diagnosed by measurement of SERCA1 activity. Since mutation analysis became more widely available, it has appeared that not all patients with reduced SERCA1 activity indeed have ATP2A1 mutations, and a distinction between Brody disease (with ATP2A1 mutations) and Brody syndrome (without ATP2A1 mutations) was proposed. We aim to compare the clinical features of patients with Brody disease and those with Brody syndrome and detect clinical features which help to distinguish between the two. In addition, we describe the Brody syndrome phenotype in more detail. We therefore performed a literature review on clinical features of both Brody disease and Brody syndrome and a cross-sectional clinical study consisting of questionnaires, physical examination, and a review of medical files in 17 Brody syndrome patients in our centre. The results showed that Brody disease presents with an onset in the 1st decade, a generalized pattern of muscle stiffness, delayed muscle relaxation after repetitive contraction on physical examination, and autosomal recessive inheritance. Patients with Brody syndrome more often report myalgia and experience a considerable impact on daily life. Future research should focus on the possible mechanisms of reduction of SERCA activity in Brody syndrome and other genetic causes, and on evaluation of treatment options. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
22. Expression of the Collagen VI α5 and α6 Chains in Normal Human Skin and in Skin of Patients with Collagen VI-Related Myopathies.
- Author
-
Sabatelli, Patrizia, Gara, Sudheer K, Grumati, Paolo, Urciuolo, Anna, Gualandi, Francesca, Curci, Rosa, Squarzoni, Stefano, Zamparelli, Alessandra, Martoni, Elena, Merlini, Luciano, Paulsson, Mats, Bonaldo, Paolo, and Wagener, Raimund
- Subjects
- *
EXTRACELLULAR matrix proteins , *CONNECTIVE tissues , *SKIN inflammation , *ATOPIC dermatitis , *GENETIC mutation , *MUSCLE diseases - Abstract
Collagen VI is an extracellular matrix protein with critical roles in maintaining muscle and skin integrity and function. Skin abnormalities, including predisposition to keratosis pilaris and abnormal scarring, were described in Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) patients carrying mutations in COL6A1, COL6A2, and COL6A3 genes, whereas COL6A5, previously designated as COL29A1, was linked to atopic dermatitis. To gain insight into the function of the newly identified collagen VI α5 and α6 chains in human skin, we studied their expression and localization in normal subjects and in genetically characterized UCMD and BM patients. We found that localization of α5, and to a lesser extent α6, is restricted to the papillary dermis, where the protein mainly colocalizes with collagen fibrils. In addition, both chains were found around blood vessels. In UCMD patients with COL6A1 or COL6A2 mutations, immunolabeling for α5 and α6 was often altered, whereas in a UCMD and in a BM patient, each with a COL6A3 mutation, expression of α5 and α6 was apparently unaffected, suggesting that these chains may substitute for α3, forming α1α2α5 or α1α2α6 heterotrimers. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
23. An Italian case of hereditary myopathy with early respiratory failure (HMERF) not associated with the titin kinase domain R279W mutation
- Author
-
Tasca, Giorgio, Mirabella, Massimiliano, Broccolini, Aldobrando, Monforte, Mauro, Sabatelli, Mario, Biscione, Gian Luca, Piluso, Giulio, Gualandi, Francesca, Tonali, Pietro Attilio, Udd, Bjarne, and Ricci, Enzo
- Subjects
- *
MUSCLE diseases , *CYTOPLASM , *IMMUNOHISTOCHEMISTRY , *GENETIC mutation , *RESPIRATORY insufficiency , *ADULTS , *NEEDLE biopsy , *GENETICS - Abstract
Abstract: Hereditary myopathy with early respiratory failure (HMERF) is a rare disorder characterized by severe respiratory involvement at onset, muscle weakness starting in the early adulthood, and cytoplasmic bodies with peculiar immunohistochemical reactivity on muscle biopsy. Here we describe a patient who presented with hypercapnic coma at age 32. A detailed light and electron microscopy analysis on muscle biopsy was performed and, together with clinical data, led to the diagnosis. The R279W mutation in the TTN gene was excluded. This report expands the geographical region of incidence and encourages additional studies to clarify the genetic heterogeneity of the condition. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
24. Antisense Modulation of Both Exonic and Intronic Splicing Motifs Induces Skipping of a DMDPseudo-Exon Responsible for X-Linked Dilated Cardiomyopathy.
- Author
-
Paola Rimessi, Marina Fabris, Matteo Bovolenta, Elena Bassi, Sofia Falzarano, Francesca Gualandi, Claudio Rapezzi, Fabio Coccolo, Daniela Perrone, Alessandro Medici, and Alessandra Ferlini
- Subjects
- *
ANTISENSE nucleic acids , *GENETIC engineering , *EXONS (Genetics) , *CARDIOMYOPATHIES , *TREATMENT of Duchenne muscular dystrophy , *GENETIC mutation - Abstract
Antisense-mediated exon skipping has been actively investigated as a treatment strategy for subsets of Duchenne muscular dystrophy mutations. This approach is based on targeting specific splicing motifs that interfere with the spliceosome assembly resulting in an in-frame deletion of a deleterious mutation. In this study, Rimessi et al.use a variety of in vitrostrategies to examine the role of intronic splicing sequences with the goal of designing improved exon skipping-mediated therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. P.25 - A common COL6A1 deep-intronic pseudo-exon inserting mutation causes a distinct phenotype of Ullrich congenital muscular dystrophy.
- Author
-
Reghan Foley, A., Donkervoort, S., Bolduc, V., Hu, Y., Cummings, B., Lek, M., Sarkozy, A., Jimenez-Mallebrera, C., Butterfield, R., Lamande, S., Kirschner, J., Allamand, V., Stojkovic, T., Quijano-Roy, S., Gualandi, F., Ferlini, A., Bertini, E., Macarthur, D., Muntoni, F., and Bönnemann, C.
- Subjects
- *
GENETIC mutation , *MUSCULAR dystrophy - Published
- 2017
- Full Text
- View/download PDF
26. S.O.6 - Transcriptomics analysis in collagen VI myopathy: Role of circadian genes using novel fluidic card tools.
- Author
-
Scotton, C., Schwartz, E., Falzarano, M., Bovolenta, M., Rossi, R., Armaroli, A., Osman, H., Gualandi, F., Neri, M., Lochmuller, H., Pesole, G., Sabatelli, P., Merlini, L., Bonaldo, P., Muntoni, F., Gelfi, C., Lebowitz, M., Esser, K., and Ferlini, A.
- Subjects
- *
MUSCLE diseases , *COLLAGEN genetics , *GENETICS of circadian rhythms , *GENETIC transcription , *GENETIC mutation , *MUSCULAR dystrophy , *GENETICS - Published
- 2016
- Full Text
- View/download PDF
27. DYT16/PRKRA founder mutation causes childhood-onset generalized dystonia in a family from Southern Italy.
- Author
-
Quadri, Marialuisa, Olgiati, Simone, Sensi, Mariachiara, Gualandi, Francesca, Groppo, Elisabetta, Rispoli, Vittorio, Graafland, Josja, Breedveld, Guido J., Fabbrini, Giovanni, and Bonifati, Vincenzo
- Subjects
- *
DYSTONIA , *GENETIC mutation , *ETIOLOGY of diseases , *JUVENILE diseases - Published
- 2016
- Full Text
- View/download PDF
28. G.P.131 - Next generation sequencing identifies a novel ATP7A mutation in two brothers with distal hereditary motor neuropathy and autonomic dysfunction.
- Author
-
Scotton, C., Italyankina, E., Storbeck, M., Vezyroglou, K., Heller, R., Neri, M., Di Raimo, F., Mauro, A., Tugnoli, V., Timmerman, V., Wirth, B., De Grandis, D., Gualandi, F., and Ferlini, A.
- Subjects
- *
DUCHENNE muscular dystrophy , *MUSCLE weakness , *DYSAUTONOMIA , *NEUROPATHY , *GENETIC mutation - Published
- 2015
- Full Text
- View/download PDF
29. O.13 Using out-of-frame exon skipping to induce IRES-driven expression of an N-truncated dystrophin isoform for 5’ DMD mutations.
- Author
-
Vulin, A., Falzarano, M.S., Szigyarto, A., Findlay, A., Vattemi, G., Perrone, D., Gualandi, F., Howard, M.T., and Flanigan, K.M.
- Subjects
- *
EXONS (Genetics) , *GENE expression , *DYSTROPHIN , *GENETIC mutation , *DUCHENNE muscular dystrophy , *SYMPTOMS - Abstract
Frame-truncating mutations within the first five exons of the DMD gene typically do not result in Duchenne muscular dystrophy, but instead result in milder dystrophinopathy syndromes. This was first demonstrated in individuals carrying the c.9G>A (p.Trp3X) mutation, a North American founder allele associated with clinical severity ranging from a very mild Becker muscular dystrophy phenotype to a complete absence of symptoms. We have previously shown that the mild phenotype associated with this and similar 5’ exon mutations is due to alternative initiation of translation from methionines encoded in exon 6, a process mediated by the presence of a muscle-specific and glucocorticoid-inducible internal ribosomal entry site (IRES) found within exon 5. The resultant N-truncated dystrophin protein lacks the first calponin homology domain of the canonical actin binding domain 1. Nevertheless, it is highly functional, raising the possibility of the therapeutic use of this isoform. We hypothesized that disruption of the mRNA open reading frame via exon skipping – resulting in a downstream premature termination codon – would stimulate IRES utilization. The feasibility of this approach is supported by the recent identification of an asymptomatic patient harbouring an exon 2 deletion, and we designed U7snRNA vectors targeting exon 2 for use in both patient-derived cell lines and in a new DMD mouse model harbouring an exon 2 duplication. Both in vitro and in vivo we can stimulate IRES activity, and by combining exon-skipping and glucocorticoid treatment we are able to restore expression of a properly localized yet N-truncated dystrophin. These results not only provide evidence for the functionality of the dystrophin IRES – and, hence, for the presence of a novel N-truncated dystrophin isoform under yet to be clarified physiologic conditions – but also suggest that out-of-frame skipping is a promising therapeutic approach for DMD patients harbouring 5’ mutations. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
30. G.P.103 Brody syndrome: a clinically heterogeneous entity distinct from Brody disease: A review of literature and a cross-sectional clinical study in 17 patients
- Author
-
Voermans, N.C., Laan, A.E., Oosterhof, A., van Kuppevelt, A., Drost, G., Lammens, M., Kamsteeg, E.J., Scotton, C., Gualandi, F., Guglielmi, V., Van den Heuvel, L., Vattemi, G., and van Engelen, B.G.M.
- Subjects
- *
SARCOPLASMIC reticulum , *GENETIC mutation , *SYSTEMATIC reviews , *RARE diseases , *PROGRESSIVE muscle relaxation , *PHENOTYPES , *CROSS-sectional method , *ADENOSINE triphosphatase - Abstract
Abstract: Brody disease is a rare inherited myopathy due to reduced sarcoplasmic reticulum Ca2+ ATPase (SERCA)1 activity caused by mutations in ATP2A1, which causes delayed muscle relaxation and silent cramps. So far the disease has mostly been diagnosed by measurement of SERCA1 activity. Since mutation analysis became more widely available, it has appeared that not all patients with reduced SERCA1 activity indeed have ATP2A1 mutations, and a distinction between Brody disease (with ATP2A1 mutations) and Brody syndrome (without ATP2A1 mutations) was proposed. We aim to compare the clinical features of patients with Brody disease and those with Brody syndrome and detect clinical features which help to distinguish between the two. In addition, we describe the Brody syndrome phenotype in more detail. We therefore performed a literature review on clinical features of both Brody disease and Brody syndrome and a cross-sectional clinical study consisting of questionnaires, physical examination, and a review of medical files in 17 Brody syndrome patients in our centre. The results showed that Brody disease presents with an onset in the 1st decade, a generalized pattern of muscle stiffness, delayed muscle relaxation after repetitive contraction on physical examination, and autosomal recessive inheritance. Patients with Brody syndrome more often report myalgia and experience a considerable impact on daily life. Future research should focus on the possible mechanisms of reduction of SERCA activity in Brody syndrome and other genetic causes, and on evaluation of treatment options. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
31. D.P.12 Whole exome sequencing and RNAseq in a Duchenne-like female with no dystrophin mutations: Search for dystrophin gene modifiers
- Author
-
Brioschi, S., Bovolenta, M., Neri, M., Scotton, C., Castrignanò, T., Pesole, G., Bertini, E., Dallapiccola, B., Kotelnikova, E., Gualandi, F., and Ferlini, A.
- Subjects
- *
NUCLEOTIDE sequence , *EXONS (Genetics) , *DUCHENNE muscular dystrophy , *GENETIC mutation , *SINGLE nucleotide polymorphisms , *BIOLOGICAL variation - Abstract
Abstract: We identified a Duchenne-like female clinically evaluated as a severely affected symptomatic DMD carrier. Carrier status was confirmed by evidence of mosaic pattern of dystrophin expression on muscle biopsy; nevertheless, extensive analysis by MLPA, sequencing, CGH-array and RNA profiling failed to identify any mutation within DMD gene. We performed whole exome sequencing by means of an Illumina GAIIe sequencer in order to identify genetic modifiers that could contribute to the symptomatic phenotype in this female. A total of 23,776 SNPs passed filtering for quality parameters. We further selected variations present in a list of 883 candidate genes belonging to the dystrophin expression regulation network and, applying a dominant model of inheritance for the modifying genes, we considered only heterozygous variations including SNPs already present in the dbSNP database. This allowed us to retain 902 SNPs. We performed RNAseq analysis on her muscle biopsy to restrict the panel of SNPs and integrated exome and transcriptome results to provide critical/confirmatory information about the SNPs identified. Eight out of the 20 SNPs selected in UTR regions were validated by RNAseq data. For non-synonymous variations, 205 out of the 219 SNPs were mapped in genes expressed in muscle and 61 were validated by RNAseq. In total we validated 69 exploratory SNPs. These SNPs are located within genes involved in the sarcolemma and extracellular matrix, cell signalling and, interestingly, chromatin modification. The 69 SNPs are in course of validation in two groups of females: symptomatic (17) and non-symptomatic (18) DMD carriers. Results will be statistically analysed using both multidimensional scaling and discriminate analysis in order to identify those variations able to discriminate between the two phenotypic groups. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
32. D.P.9 Whole exome sequencing filtered by novel candidate genes as tool for gene discovery in a recessive family with Parkinson and ataxia
- Author
-
Neri, M., Bovolenta, M., Scotton, C., De Grandis, D., Castrignanò, T., Dallapiccola, B., Gualandi, F., and Ferlini, A.
- Subjects
- *
NUCLEOTIDE sequence , *PARKINSON'S disease & genetics , *ATAXIA , *EXONS (Genetics) , *ADRENOLEUKODYSTROPHY , *GENETIC mutation - Abstract
Abstract: We studied a family of four with a form of juvenile Parkinson, cognitive impairment, ataxia, and obesity, with variable clinical severity. Many genes associated to these diseases were excluded with conventional sequencing: SCA1, SCA2, SCA3, SCA6 and DRPLA for the spinocerebellar ataxias, GM1 and GM2 for the adrenoleukodystrophy, GCH1 for dopa-responsive dystonia and the linkage analysis excluded the Parkinson genes PARK2, PARK3 and PARK7. For both affected patients we hypothesized a neurological disease with multisystem involvement that was genetically determined. We performed the whole exome sequencing analysis by Illumina GAIIe platform on all family members except the affected sister. We identified a mean of 30,000 SNPs or DIPs passing a quality filters (coverage >10, ambigously mapped reads per variant <5, Phred-scaled consensus quality >50, variant confidence/consensus quality >1.5). We elaborated a list of 143 genes that are frankly or putatively associated to Parkinson, obesity or spinocerebellar ataxia and adopted this list as a filter applied to the WES analysis, considering SNPs only in homozygosity or in compound heterozygosity (dbSNPs not excluded). This analysis allowed us to detect 82 variations within 41 genes in homozygosity and 134 variations in compound heterozygosity within 39 genes. We filtered these identified variations in family’s members or in other samples present in the same run; this investigation greatly reduced the numbers of variations, being now 12 homozygous and 54 the compound heterozygous. The variations identified are in course of technical validation as possible mutations in novel genes causing the peculiar phenotype in this family. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
33. D.P.7 Whole exome sequencing as genetic diagnostic tool in myofibrillar myopathies
- Author
-
Neri, M., Bovolenta, M., Scotton, C., Castrignanò, T., Vattemi, G.A.G., Schwartz, E., Daraselia, N., Kotelnikova, E., Gualandi, F., and Ferlini, A.
- Subjects
- *
GENETIC disorder diagnosis , *MEDICAL equipment , *MUSCLE diseases , *MYOFIBRILS , *IMMUNOHISTOCHEMISTRY , *GENETIC mutation , *BIOINFORMATICS - Abstract
Abstract: Myofibrillar myopathies (MFM) represents a group of neuromuscular disorders either familial or sporadic with clinical and genetic heterogeneity. To date, mutations in six genes are known to cause MFM, but a large number of these diseases are caused by so far unidentified gene defects. Within the NMD-chip project, we had previously studied by CGH arrays 21 sporadic patients with a clinical and immunohistochemical diagnosis of myofibrillar myopathy negative at conventional sequencing for small mutations in desmin, αB-crystallin, myotilin, Z-band alternatively spliced PDZ motif containing protein (ZASP) Bcl2-associated athanogene 3 (BAG3). The CGH analysis did not reveal any rearrangement in myofibrillar myopathy known genes. We have therefore run whole exome sequencing (WES) by Illumina GAIIe platform in seven out our 21 negative patients. This approach has allowed us to identified a mean of 60,000 SNPs or DIPs passing standard quality filters. We applied a further bioinformatics filter consisting in 880 candidate genes selected using the MedScan interactome pathway developed by Ariadne Genomics. We looked at SNPs or DIPs occurring in heterozygosity (according with a dominant model of inheritance) within all these genes. All SNPs already reported in the dbSNP database were excluded. This analysis led to the identification of a mean of 10 variations/patient. We detected (in heterozygosis) a nonsense and a missense variations in Filamin C, and 3 missense variations in three unrelated patients, within the Titin gene. Mutations in this huge gene, are known to cause a recessive form of LGMD (LGMD2J), but have not been previously related to MFMs. We have also identified stop mutations in other three novel possibly causative genes. All variations are in course of validation. We demonstrate here that WES, following facilitation of both molecular and bioinformatics procedures, may represent a “second step” powerful diagnostic tool in NMDs with high genetic heterogeneity. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.